email article
Since the early days of the pandemic, researchers have been trying to use old drugs for new tricks, raising hopes and spurring controversy. Some of these, like hydroxychloroquine, turned out to be flops, while others are still debated. Recently, another old drug called fluvoxamine has come onto the scene.
MedPage Today explores how the old antidepressant has made its way to the COVID spotlight.
Fluvoxamine and the COVID Early Treatment Fund
Fluvoxamine is the poster child of the COVID-19 Early Treatment Fund (CETF). According to its founder, serial tech entrepreneur Steve Kirsch, CETF was started in April 2020 in order to fund drug repurposing research to find the fastest and most cost-effective early outpatient treatments for COVID-19. Kirsch told
Growing worries that AstraZeneca Plc’s Covid-19 vaccine causes rare blood clots could hinder immunization campaigns across the world, from London to Seoul. Reviews by UK and European Union regulators finding potential links to the unusual side effects are another blow for the shot, a cheaper and easier-to-deploy product that many nations are counting on in a bid to end the pandemic. Safety concerns could shake confidence in the injection, even though regulators reiterated that its benefits outweigh the risks. Many regions are turning their attention to vaccines from Johnson & Johnson and developers in China, Russia and elsewhere, but they’re still in a difficult position with demand for doses far outstripping supply.
Apr 8, 2021, 1:00 AM – Updated on Apr 8, 2021, 11:22 AM
Word Count: 974
Reviews by U.K. and European Union regulators finding potential links to the unusual side effects are another blow for the shot, a cheaper and easier-to-deploy product that many nations are counting on in a bid to end the pandemic.
Safety concerns could shake confidence in the injection, even though regulators reiterated that its benefits outweigh the risks. Many regions are turning their attention to vaccines from Johnson & Johnson and developers in China, Russia and elsewhere, but they’re still in a difficult position with demand for doses far outstripping supply.
“Better Astra than nothing,” said Michael Kinch, a drug development expert and associate vice chancellor at Washington University in St. Louis. “In an under-vaccinated country, I think you have no choice but to take it.”
AstraZeneca clot worries complicate bid to vaccinate the world japantimes.co.jp - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from japantimes.co.jp Daily Mail and Mail on Sunday newspapers.
I’ve covered arts and entertainment and written humor columns at The Day for almost a quarter-century. What I’ve learned is how privileged I’ve been to explore for readers an incredibly diverse, active, and creative cultural area – from local music clubs, galleries and museums to numerous nationally famous authors, performance organizations and the array of talent that flows through the Garde Arts Center, and Mohegan Sun and Foxwoods casinos, and much more.
Rick Koster
I’ve covered arts and entertainment and written humor columns at The Day for almost a quarter-century. What I’ve learned is how privileged I’ve been to explore for readers an incredibly diverse, active, and creative cultural area – from local music clubs, galleries and museums to numerous nationally famous authors, performance organizations and the array of talent that flows through the Garde Arts Center, and Mohegan Sun and Foxwoods casinos, and much more.